Recent Advances in Pharmaceutical Cocrystals: From Bench to Market.
cocrystallization
formulation
particle size
permeability
pharmaceutical cocrystals
regulatory guidelines
solid dosage forms
solubility
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
09
2021
accepted:
11
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
4
12
2021
Statut:
epublish
Résumé
The pharmacokinetics profile of active pharmaceutical ingredients (APIs) in the solid pharmaceutical dosage forms is largely dependent on the solid-state characteristics of the chemicals to understand the physicochemical properties by particle size, size distribution, surface area, solubility, stability, porosity, thermal properties, etc. The formation of salts, solvates, and polymorphs are the conventional strategies for altering the solid characteristics of pharmaceutical compounds, but they have their own limitations. Cocrystallization approach was established as an alternative method for tuning the solubility, permeability, and processability of APIs by introducing another compatible molecule/s into the crystal structure without affecting its therapeutic efficacy to successfully develop the formulation with the desired pharmacokinetic profile. In the present review, we have grossly focused on cocrystallization, particularly at different stages of development, from design to production. Furthermore, we have also discussed regulatory guidelines for pharmaceutical industries and challenges associated with the design, development and production of pharmaceutical cocrystals with commercially available cocrystal-based products.
Identifiants
pubmed: 34858194
doi: 10.3389/fphar.2021.780582
pii: 780582
pmc: PMC8632238
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
780582Informations de copyright
Copyright © 2021 Kumar Bandaru, Rout, Kenguva, Gorain, Alhakamy, Kesharwani and Dandela.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Pharm. 2019 Jul 1;16(7):3167-3177
pubmed: 31117742
Adv Drug Deliv Rev. 2017 Aug 1;117:162-177
pubmed: 28811184
Chem Commun (Camb). 2009 Mar 28;(12):1439-51
pubmed: 19277355
Int J Pharm. 2019 Jul 20;566:745-755
pubmed: 31212053
Mol Pharm. 2018 Sep 4;15(9):3741-3754
pubmed: 29166563
Int J Pharm. 2016 Jun 15;506(1-2):68-78
pubmed: 27073084
Cryst Growth Des. 2020 Jul;20(7):4335-4345
pubmed: 33935595
Chem Commun (Camb). 2012 Nov 28;48(92):11340-2
pubmed: 23073186
Trends Pharmacol Sci. 2013 Mar;34(3):185-93
pubmed: 23347591
J Pharm Sci. 2013 Feb;102(2):311-7
pubmed: 23192888
Pharm Res. 2002 Oct;19(10):1564-71
pubmed: 12425477
Bioimpacts. 2018;8(4):305-320
pubmed: 30397585
Eur J Pharm Sci. 2014 Oct 1;62:251-7
pubmed: 24931188
Eur J Pharm Sci. 2014 Oct 15;63:124-31
pubmed: 24995701
Cryst Growth Des. 2008;8(1):14-16
pubmed: 19367342
Anal Chem. 2015 Jun 2;87(11):5458-69
pubmed: 25794311
Int J Pharm. 2018 Aug 25;547(1-2):404-420
pubmed: 29890258
Acta Pharm Sin B. 2019 Jan;9(1):59-73
pubmed: 30766778
Adv Drug Deliv Rev. 2016 Jun 1;101:143-166
pubmed: 27137109
Mol Pharm. 2006 May-Jun;3(3):362-7
pubmed: 16749868
Ultramicroscopy. 2020 Jun;213:112977
pubmed: 32361281
Appl Microsc. 2020 Jun 16;50(1):12
pubmed: 33580349
Int J Pharm. 2015 Feb 1;479(1):118-28
pubmed: 25542989
J Pharm Sci. 2014 Sep;103(9):2904-2910
pubmed: 24807421
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1019-30
pubmed: 23685353
ACS Omega. 2018 Feb 28;3(2):2406-2416
pubmed: 30023832
Molecules. 2015 Aug 14;20(8):14833-48
pubmed: 26287141
Int J Pharm. 2013 Aug 30;453(1):101-25
pubmed: 23207015
Pharm Res. 2008 May;25(5):999-1022
pubmed: 18040761
Pharm Res. 2010 Dec;27(12):2725-33
pubmed: 20872053
Pharmaceutics. 2011 Oct 12;3(4):706-22
pubmed: 24309304
Adv Drug Deliv Rev. 2017 Aug 1;117:178-195
pubmed: 28712924
Anal Bioanal Chem. 2010 Jun;397(3):1009-17
pubmed: 20386888
J Pharm Pharmacol. 2010 Nov;62(11):1547-59
pubmed: 21039540
Mol Pharm. 2007 May-Jun;4(3):347-54
pubmed: 17497885
Drug Discov Today. 2008 May;13(9-10):440-6
pubmed: 18468562
Int J Pharm. 2012 Apr 15;426(1-2):15-20
pubmed: 22274588
Acta Crystallogr C. 2007 Feb;63(Pt 2):o129-31
pubmed: 17348096
J Pharm Sci. 2010 Apr;99(4):1693-6
pubmed: 19774652
Drug Dev Ind Pharm. 2015;41(12):1935-47
pubmed: 26133085
Cryst Growth Des. 2009 Jun 3;9(6):2950-2967
pubmed: 19503732
Int J Pharm. 2015 Feb 1;479(1):227-40
pubmed: 25541517
Int J Pharm. 2020 Jun 30;584:119454
pubmed: 32464230
Pharmaceutics. 2018 Oct 16;10(4):
pubmed: 30332804
ADMET DMPK. 2019 Apr 05;7(2):106-130
pubmed: 35350544
Drug Discov Today. 2019 Mar;24(3):796-804
pubmed: 30521935
Mol Pharm. 2017 Nov 6;14(11):3879-3887
pubmed: 28990387
AAPS PharmSciTech. 2016 Feb;17(1):20-42
pubmed: 26159653
Int J Pharm. 2018 Nov 15;551(1-2):241-256
pubmed: 30223079
Eur J Pharm Biopharm. 2016 Oct;107:151-9
pubmed: 27395394
Int J Pharm. 2019 Mar 10;558:426-440
pubmed: 30664997
J Pharm Sci. 2017 Feb;106(2):457-470
pubmed: 27914793